The clinical information you need, at your fingertips.

Medical News for You

AHA Hypertension 2026

30m

Hidden high blood pressure at home linked to more falls in older adults

Older adults with masked hypertension faced substantially higher fall risk despite normal clinic blood pressure readings. . .

JAMA Netw Open

Hidden steroids found in popular skin creams

One in three targeted over-the-counter products contained an undisclosed prescription-strength corticosteroid. . .

Company news

Long-acting Cabenuva outperforms daily oral therapy in unsuppressed HIV

Six-month CROWN findings suggest injections could expand treatment options for people who have not achieved viral suppression. . .

J Hepatol

Resmetirom or semaglutide for MASH? New guidance helps clinicians choose

Updated European recommendations clarify who qualifies, which drug to prioritize, and when to reassess treatment. . .

AHA Hypertension 2026

Is the DASH diet safe for patients on potassium-raising drugs?

A pooled analysis found no link between potassium-rich DASH groceries and hyperkalemia among Black adults taking medications that can raise potassium. . .

JAMA Netw Open

Oral semaglutide caught on quickly after obesity approval

Real-world data suggest the first oral GLP-1 receptor agonist approved for obesity rapidly entered clinical practice, with many users new to GLP-1 therapy. . .

FDA

FDA approves Tukysa, frontline maintenance therapy for HER2-positive metastatic breast cancer

An oral add-on to trastuzumab and pertuzumab extends progression-free survival. . .

Drug pipeline

10h

New Parkinson’s drug reduces OFF time without targeting dopamine

Phase 3 trial found about 37 fewer minutes of daily symptoms versus placebo, with improvements in everyday motor function. . .

Science

13h

Gut microbes may help explain fever after vaccination

Bacterial proteins linked to inflammation could offer a future target for reducing reactions without weakening antibody responses. . .

epocrates

18h

Test created by integration tests

Hadlima (adalimumab) - indicated for 1) moderate to severe rheumatoid arthritis in adult patients, 2) psoriatic arthritis in adult patients, 3) ankylosing spondylitis in adult patients, 4) moderate to severe Crohn disease in adult and pediatric patients 6 years and older, 5) various other indications.